Pharmaceuticals, Biotechnology and Life Sciences
Vancouver-based drugmaker OncoGenex didn’t make any revenues in the fourth quarter 2016, and it finished the year with a net loss for the fourth quarter and year ended December 31, 2016 of $5.8 million and $20.1 million, respectively.
Oxford BioMedica, a gene and cell therapy group, has presented results from a Phase I/II clinical trial of MVA-5T4 immunotherapy (TroVax) and low dose cyclophosphamide (CPM) in patients with advanced colorectal cancer (TaCTiCC).
Canada-based drugmaker Valeant Pharmaceuticals was put in focus for an online stock market analyist among several other healthcare companies. Valeant and EyeGate inked a deal for worldwide commercial and manufacturing rights to a product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
Abivax, a biotechnology company targeting the immune system to eliminate viral diseases, has recently discovered several molecules that are active against the virus in vitro, some of which could be developed as therapeutic drug-candidates against dengue fever.
Oxford Pharmascience’s interim PK study showed that the technolology modifications can not only make OXPzero Ibuprofen bioequivalent to OTC Nurofen, but also potentially faster acting, the drugmaker said in an update on OXPzero Ibuprofen clinical program, for which on January 17, it kicked off dosing healthy patients in the first phase of the study.
US Food and Drug Administration (FDA) has accepted Novartis’s supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
PureTech Health has named new Chief Medical Officer to see all clinical operations across its pipeline and will focus on pushing chances that have most potential for patients.
PMV Pharmaceuticals, Inc., a cancer focused developer of p53-targeted small molecule drugs, has completed a Series B financing round bagging $74 million.
BD said on Wednesday that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new Food and Drug Administration’s (FDA’s) performance requirements.